Upgraded Views On Organogenesis

Analysts have made substantial upgrades to this year's forecasts for Organogenesis. The consensus numbers for both revenue and earnings per share (EPS) increased, with their view clearly much more bullish on the company's business prospects. The stock price has risen over the past week, suggesting investors are becoming more optimistic. 

Following the upgrades, the latest consensus from Organogenesis Holdings' four analysts is for revenues of US$397m in 2021, which would reflect a major 30% improvement in sales compared to the last 12 months. The losses are expected to disappear over the next year or so, with forecasts for a profit of US$0.035 per share this year. Yet prior to the latest estimates, the analysts had been forecasting revenues of US$343m and losses of US$0.075 per share in 2021. It looks like there's been a definite improvement in business conditions, with a revenue upgrade supposed to lead to profitability sooner than previously forecast.

Analysts have increased their price target for Organogenesis Holdings 45% to US$21.00 on the back of these upgrades. There's another way to think about price targets though, and that's to look at the range of price targets put forward by analysts, because a wide range of estimates could suggest a diverse view on possible outcomes for the business. There are some variant perceptions on Organogenesis Holdings, with the most bullish analyst valuing it at US$21.00 and the most bearish at US$13.00 per share.

https://finance.yahoo.com/news/brokers-upgrading-views-organogenesis-holdings-144955163.html